

TABLE OF CONTENTS

Section	Page
Title	i
Declaration	iii
Certificate 1	iv
Certificate 2	v
Dedication	vi
Acknowledgements	vii
General Abstract	ix
List of Publications	xiv
Table of contents	xv
List of tables	xxiii
List of figures	xxvii
List of abbreviations	xxxii
Chapter 1	
1.1. General introduction	1
1.2. Review of literature	10
1.3. Aims and objectives	84
Chapter 2 <i>Clinico-bacteriological study for the isolation and characterization of Mycoplasma species from the nasal swabs of goats in Balochistan</i>	85
Abstract	86
2.1. Introduction	88
2.2. Materials and methods	90
2.2.1. Study area	90
2.2.2. Study animals, sample size, and sampling procedure	90
2.2.3. Clinical picture, isolation and characterization of mycoplasmas from the nasal swabs of goats	91
2.2.3.1. Clinical picture	91
2.2.3.2. Collection and processing of samples	91
2.2.3.3. Bacteriological culture medium for the isolation of mycoplasmas	91
2.2.3.3.1. Modified CCPP broth medium	92
2.2.3.3.2. Modified CCPP agar medium	92
2.2.3.4. Bacteriological procedure for the isolation of <i>Mycoplasma</i> species	93
2.2.3.5. Preliminary identification of the mycoplasma isolates	94
2.2.3.5.1. Digitonin sensitivity test	94
2.2.3.5.2. Growth of mycoplasma isolates in serum non-enriched modified CCPP media	95
2.2.3.6. Biochemical characterization of <i>Mycoplasma</i> species	95
2.2.3.6.1. Glucose fermentation test	96
2.2.3.6.2. Arginine hydrolysis test	96
2.2.3.6.3. Phosphatase production test	97
2.2.3.6.4. Tetrazolium reduction test	98
2.2.3.6.5. Casein hydrolysis test	99

2.2.3.6.6.	Liquifaction of inspissated serum medium	99
2.2.3.6.7.	Film and spot production test	100
2.2.3.7.	Serological characterization of <i>Mycoplasma</i> species	101
2.2.3.7.1.	Growth inhibition test (GIT)	101
2.2.3.8.	Preservation of the biochemically and serologically characterized mycoplasmas isolates	102
2.2.4.	Data analysis	102
2.3.	Results	102
2.3.1.	Clinical picture, isolation and characterization of mycoplasmas from the nasal swabs of goats	103
2.3.1.1.	Clinical picture	103
2.3.1.2.	Bacteriological procedure for the isolation of <i>Mycoplasma</i> species	103
2.3.1.3.	Preliminary identification of the mycoplasma isolates	107
2.3.1.3.1.	Digitonin sensitivity test and growth of mycoplasmas isolates in serum non-enriched modified CCPP media	107
2.3.1.4.	Biochemical characterization of <i>Mycoplasma</i> species	107
2.3.1.5.	Serological characterization of <i>Mycoplasma</i> species	108
2.3.1.5.1.	Growth inhibition test (GIT)	108
2.3.1.6.	Isolation and characterization of mycoplasmas from the nasal swab samples	108
2.4.	Discussion	126
2.5.	Conclusions	135
Chapter 3	<i>Gross-pathological and bacteriological study for the isolation and characterization of Mycoplasma species from the lungs of goats in Balochistan</i>	136
	Abstract	137
3.1.	Introduction	139
3.2.	Materials and methods	142
3.2.1.	Study area	142
3.2.2.	Study animals, sample size, and sampling procedure	142
3.2.3.	Gross-pathological lesions, isolation and characterization of mycoplasmas from the lung samples of the slaughtered goats	143
3.2.3.1.	Gross-pathology of the lungs	143
3.2.3.2.	Processing of lung samples for the isolation of mycoplasmas	143
3.2.3.3.	Bacteriological culture media and procedure for the isolation and identification of <i>Mycoplasma</i> species	143
3.2.3.4.	Biochemical characterization of <i>Mycoplasma</i> species	144
3.2.3.5.	Serological identification of <i>Mycoplasma</i> species	144
3.2.3.5.1.	Growth inhibition test (GIT)	144
3.2.3.6.	Preservation of the biochemically and serologically identified mycoplasmas isolates	144
3.2.4.	Data analysis	144
3.3.	Results	145
3.3.1.	Gross-pathological lesions, isolation and characterization of mycoplasmas from the lung samples of the slaughtered goats	145
3.3.1.1.	Gross pathology of lungs	145
3.3.1.2.	Isolation of <i>Mycoplasma</i> species	151
3.3.1.3.	Preliminary identification of the mycoplasma isolates	151

3.3.1.4.	Biochemical characterization of <i>Mycoplasma</i> species	151
3.3.1.5.	Serological identification of <i>Mycoplasma</i> species	152
3.3.1.5.1.	Growth inhibition test (GIT)	152
3.3.1.6.	Isolation and characterization of <i>Mycoplasma</i> species from the lung samples	152
3.3.1.7.	Gross-pathology and isolation of <i>Mycoplasma</i> species from the lungs of goats	154
3.4.	Discussion	163
3.5.	Conclusions	170
Chapter 4	<i>Clinico-pathological and bacteriological study on pleuropneumonia suspected goats in Balochistan</i>	172
	Abstract	173
4.1.	Introduction	175
4.2.	Materials and methods	179
4.2.1.	Study area	179
4.2.2.	Study animals, sample size, and sampling procedure	180
4.2.3.	Clinical picture in the pleuropneumonia suspected goats	180
4.2.4.	Postmortem examination of the pleuro-pneumonia suspected goats for the gross pathological lesions	180
4.2.5.	Isolation and identification of mycoplasmas from the pleuropneumonia suspected goats	181
4.2.5.1.	Bacteriological culture media and procedure for the isolation and identification of <i>Mycoplasma</i> species	181
4.2.5.2.	Biochemical characterization of <i>Mycoplasma</i> species	182
4.2.5.3.	Serological identification and storage of <i>Mycoplasma</i> species	182
4.2.6.	Data analysis	182
4.3.	Results	183
4.3.1.	Clinico-pathologic and bacteriological study for the pleuropneumonia suspected goats	183
4.3.1.1.	Clinical picture of the pleuro-pneumonia suspected goats	183
4.3.1.2.	Gross pathology in the pleuropneumonia suspected goats	183
4.3.1.3.	Isolation and characterization of mycoplasmas from the pleuropneumonia suspected goats	191
4.4.	Discussion	201
4.5.	Conclusions	208
Chapter 5	<i>The use of polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), and denaturing gradient gel electrophoresis (DGGE) in the identification of Mycoplasma species isolated from goats in Balochistan</i>	210
	Abstract	211
5.1.	Introduction	213
5.2.	Materials and methods	216
5.2.1.	Mycoplasma isolates	216
5.2.2.	Extraction of DNA from the mycoplasma isolates	217
5.2.2.1.	Purity of DNA samples	219
5.2.3.	Polymerase chain reaction (PCR)	219

5.2.3.1.	PCR for the detection of <i>Mycoplasma mycoides</i> cluster members	219
5.2.3.1.1.	Procedure for PCR	220
5.2.3.2.	PCR for the detection of <i>Mycoplasma mycoides</i> sub-cluster members	220
5.2.3.2.1.	Procedure for PCR	220
5.2.3.3.	PCR for the specific detection of <i>Mycoplasma capricolum</i> subspecies <i>capripneumoniae</i> (<i>Mccp</i>)	222
5.2.3.3.1.	Procedure for PCR	222
5.2.3.4.	PCR for the specific detection of <i>Mycoplasma putrefaciens</i> (<i>Mp</i>)	222
5.2.3.4.1.	Procedure for PCR	223
5.2.3.5.	PCR for the specific detection of <i>Mycoplasma arginini</i> and <i>Acholeplasma</i> organisms	223
5.2.3.6.	Agarose gel electrophoresis	223
5.2.4.	Restriction fragment length polymorphism (RFLP) for <i>Mycoplasma</i> species	224
5.2.4.1.	Restriction fragment length polymorphism (RFLP) for the <i>Mycoplasma mycoides</i> sub-cluster PCR product	224
5.2.4.1.1.	Procedure for RFLP	224
5.2.4.2.	Restriction fragment length polymorphism (RFLP) for the <i>Mycoplasma capricolum</i> subspecies <i>capripneumoniae</i> (<i>Mccp</i>) PCR product	225
5.2.4.3.	Specific PCR for the detection and differentiation of mycoplasma isolates by DGGE	225
5.2.4.3.1.	Procedure for PCR	225
5.2.4.3.2.	Procedure for DGGE gel preparation	226
5.2.4.3.3.	Procedure for DGGE	226
5.3.	Results	227
5.3.1.	PCR results	227
5.3.2.	RFLP results	232
5.3.4.	DGGE results	232
5.3.5.	Comparison of classical tests, PCRs and DGGE	233
5.4.	Discussions	238
5.5.	Conclusions	241
Chapter 6	<i>Molecular prevalence of Mycoplasma species by polymerase chain reaction (PCR) directly from the nasal swab and lung tissue samples of goats in Balochistan</i>	242
	Abstract	243
6.1.	Introduction	245
6.2.	Materials and methods	247
6.2.1.	Samples for DNA extraction	247
6.2.2.	Extraction of DNA	248
6.2.2.1.	Nasal swabs	248
6.2.2.2.	Lung tissues	248

6.2.3.	Polymerase chain reaction (PCR)	248
6.2.3.1.	PCR for the detection of <i>Mycoplasma mycoides</i> cluster members	249
6.2.3.2.	PCR for the detection of <i>Mycoplasma mycoides</i> sub-cluster members	249
6.2.3.3.	PCR for the specific detection of <i>Mycoplasma capricolum</i> subspecies <i>capripneumoniae</i> (<i>Mccp</i>)	249
6.2.3.4.	PCR for the specific detection of <i>Mycoplasma putrefaciens</i> (<i>Mp</i>)	250
6.2.3.5.	PCR for the detection of <i>Mycoplasma capricolum</i> subspecies <i>capricolum</i> (<i>Mcc</i>)	250
6.2.3.6.	Agarose gel electrophoresis	250
6.2.4.	Restriction fragment length polymorphism (RFLP) for the <i>Mycoplasma</i> species	251
6.2.4.1.	RFLP for the <i>Mycoplasma mycoides</i> sub-cluster PCR product	251
6.2.4.2.	RFLP for the <i>Mycoplasma capricolum</i> subspecies <i>capripneumoniae</i> (<i>Mccp</i>) PCR product	251
6.2.5.	Data analysis	251
6.3.	Results	252
6.3.1.	Molecular prevalence (PCR-RFLP) of <i>Mycoplasma</i> species in the nasal swabs of goats	252
6.3.2.	Molecular prevalence (PCR-RFLP) of <i>Mycoplasma</i> species in the lung samples of goats	252
6.3.3.	Molecular detection (PCR-RFLP) of <i>Mycoplasma</i> species from the lung samples of pleuropneumonia suspected goats	253
6.3.4.	RFLP results	253
6.3.5.	Comparison of the results of summary data for the molecular prevalence of <i>Mycoplasma</i> species	254
6.4.	Discussions	265
6.5.	Conclusions	269
Chapter 7	<i>Standardization and use of latex agglutination test (LAT) for sero-prevalence of Mycoplasma mycoides subspecies mycoides large colony (MmmLC) in goats in Balochistan and its comparison with indirect haemagglutination assay (IHA)</i>	270
	Abstract	271
7.1.	Introduction	273
7.2.	Materials and methods	277
7.2.1.	Standardization of LAT and IHA with <i>MmmLC</i>	277
7.2.1.1.	Latex agglutination test (LAT)	277
7.2.1.1.1.	Extraction of capsular polysaccharide (CPS) from <i>MmmLC</i> culture	277
7.2.1.1.2.	Determination of carbohydrate concentration in the extracted CPS	279

7.2.1.1.3.	Purity of CPS	279
7.2.1.1.4.	Coating of latex beads with CPS	279
7.2.1.1.5.	Procedure for latex agglutination test	280
7.2.1.2.	Standardization of indirect hemagglutination assay (IHA)	280
7.2.1.2.1.	Preparation of mycoplasma antigen for IHA test	281
7.2.1.2.2.	Glutaraldehyde fixed sheep RBC	281
7.2.1.2.3.	IHA test procedure	282
7.2.1.3.	Source of anti-sera used in the standardization of LAT and IHA	283
7.2.1.4.	Sensitivity and specificity of LAT and IHA	283
7.2.1.5.	Sero-prevalence of <i>Mmm</i> LC by LAT and IHA	284
7.2.16.	Statistical analysis	284
7.3.	Results	284
7.3.1.	Latex agglutination test (LAT)	284
7.3.1.1.	Purity and concentration of CPS extracted from <i>Mmm</i> LC	284
7.3.1.2.	Reactivity of the CPS sensitized latex beads	285
7.3.2.	Indirect haemagglutination assay (IHA)	285
7.3.3.	Sensitivity and specificity of LAT and IHA	285
7.3.4.	Sero-prevalence of <i>Mmm</i> LC by LAT and IHA in goats in three districts of Balochistan	286
7.4.	Discussions	293
7.5.	Conclusions	296
Chapter 8	<i>Establishment of an experimental disease in goats with Mycoplasma species isolated from pleuropneumonia suspected goats in Balochistan</i>	297
	Abstract	298
8.1.	Introduction	300
8.2.	Materials and methods	303
8.2.1.	<i>Mycoplasma</i> species used in the experimental infection	303
8.2.2.	Goat used in the experimental infection	304
8.2.3.	Inoculation of goats with the <i>Mycoplasma</i> species	304
8.2.4.	Collection of samples from the experimental goats	305
8.2.5.	Isolation of <i>Mycoplasma</i> species from the samples	305
8.2.6.	Identification of <i>Mycoplasma</i> species	306
8.2.7.	Biochemical identification	306
8.2.8.	Serological (GIT) identification	306
8.2.9.	Molecular identification of the re-isolated <i>Mycoplasma</i> species by PCR and PCR-RFLP	307
8.2.9.1.	PCR for the detection of <i>Mycoplasma mycoides</i> cluster	307
8.2.9.2.	PCR for the identification of <i>Mycoplasma mycoides</i> sub-cluster	307
8.2.9.3.	PCR for the specific detection of <i>Mycoplasma putrefaciens</i> (<i>Mp</i>)	308
8.3.	Results	308
8.3.1.	Clinical and pathological findings in experimental goats	308
8.3.2.	Bacteriological, serological and molecular results of the	310

	experimental goats	
8.3.3.	Detection of antibodies against MmmLC in the experimental goats by LAT and IHA	313
8.4.	Discussion	320
8.5.	Conclusions	325
Chapter 9	<i>Preparation, use and evaluation of an experimental caprine pleuropneumonia vaccine against Mycoplasma species in Balochistan.</i>	326
	Abstract	327
9.1.	Introduction	329
9.2.	Materials and methods	333
9.2.1.	Source and characteristics of <i>Mycoplasma</i> species for vaccine preparation	333
9.2.2.	Inactivation of <i>MmmLC</i> by saponin and formalin	333
9.2.3.	Preparation, use, challenge and protection for <i>MmmLC</i> vaccine	334
9.2.3.1.	Use of <i>MmmLC</i> master seed for vaccine preparation	334
9.2.3.2.	Mass scale production of <i>MmmLC</i>	334
9.2.3.3.	Inactivation of <i>MmmLC</i> cell suspension with saponin and formalin	335
9.2.3.4.	Sterility, innocuity, safety and protein determination tests for <i>MmmLC</i>	335
9.2.3.4.1.	Sterility test	335
9.2.3.4.2.	Innocuity test	335
9.2.3.4.3.	Safety test	336
9.2.3.4.4.	Protein determination of <i>MmmLC</i> cell suspension	336
9.2.3.5.	Preparation of <i>MmmLC</i> based inactivated vaccine (bacterin)	337
9.2.3.5.1.	Preparation of saponin and aluminium hydroxide gel adjuvated <i>MmmLC</i> vaccine with different protein concentrations	337
9.2.3.5.2.	Dispensation of <i>MmmLC</i> vaccines	337
9.2.3.6.	Selection of goats for vaccination trial	338
9.2.3.7.	Experimental design	338
9.2.3.8.	First vaccination	338
9.2.3.9.	Second vaccination (Booster dose)	339
9.2.4.0.	Quantification of antibodies by IHA test	339
9.2.4.1.	Challenge and protection of vaccinated goats with the field strain of <i>MmmLC</i>	339
9.2.4.1.1.	Challenge with <i>MmmLC</i>	339
9.2.4.1.2.	Clinical examination and collection of Blood sample	340
9.2.4.1.3.	Post-mortem examination and bacteriology	340
9.2.4.1.4.	Quantification of antibodies by IHA test	340
9.3.	Results	340
9.3.1.	Inactivation of <i>MmmLC</i> by saponin and formalin	340
9.3.2.	Preparation, use, challenge and protection test of <i>MmmLC</i>	341

	vaccine	
9.3.2.1.	Reactivation and up scaling of <i>MmmLC</i> culture	341
9.3.2.2.	Inactivation of <i>MmmLC</i> cell suspension with saponin and formalin	347
9.3.2.3.	Sterility, innocuity, safety and protein determination tests for <i>MmmLC</i>	347
9.3.2.4.	Dispensation of <i>MmmLC</i> vaccines with saponin and aluminum hydroxide gel	347
9.3.2.5.	Post-vaccination examination of goats	348
9.3.2.6.	Post-vaccination quantification of antibodies in goats by IHA test	348
9.3.2.6.1.	<i>MmmLC</i> saponated vaccines	348
9.3.2.6.2.	<i>MmmLC</i> aluminum hydroxide gel vaccines	351
9.3.2.6.3.	Comparison of saponin and aluminum hydroxide gel adjuvated <i>MmmLC</i> vaccines	351
9.3.2.7.	Challenge and protection of vaccinated goats with the field strain of <i>MmmLC</i>	354
9.3.2.7.1.	Clinico-pathological examinations, isolation and identification of <i>Mycoplasma</i> species	354
9.3.2.7.2.	Post-challenge mortality in goats	360
9.3.2.7.3.	Post-challenge antibody profiles in goats vaccinated with <i>MmmLC</i> based adjuvated vaccines	360
9.3.2.7.3.1.	<i>MmmLC</i> saponated vaccines	360
9.3.2.7.3.2.	<i>MmmLC</i> aluminum hydroxide gel vaccines	361
9.4.	Discussion	363
9.5.	Conclusions	368
Chapter 10		
10.1	General discussion	369
10.2	General conclusions	377
References		380
Appendices		
Appendix 1		
Appendix 2		